¹⁷⁷Lu-PSMA first successful therapy performed in east Africa: A case report from mulago national referral hospital, Kampala, Uganda

Lutetium-177 prostate-specific membrane antigen (¹⁷⁷Lu-PSMA) radioligand therapy (RLT) is an important form of treatment for prostate cancer (PCa) patients. Since 2016, TPSA had been stable below 0.2 ng/mL until November 2022 when TPSA had increased to 0.61 ng/ mL, doubling in just 3 months in keeping with biochemical recurrence. A gallium-68 (⁶⁸Ga)-PSMA PET/CT scan performed showed ⁶⁸Ga-PSMA avid PCa metastases in infra and supradiaphragmatic lymph nodes. The patient was discharged after the 24 hours imaging with a radiation of 4.0 μSv/hour at 1-m distance. ¹⁷⁷Lu-PSMA RLT is an important treatment option for PCa patients. However, its access is very limited in resource-limited/constrained areas. Our case is an excellent example of how RLT can be rolled out/made available to patients who qualify and need this form of treatment among PCa patients in resource-constrained regions like Uganda.